Genenta Science S.p.A.
GNTA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.37 | -0.19 | -0.21 | 0.00 |
| FCF Yield | -8.14% | -13.75% | -7.96% | -3.97% |
| EV / EBITDA | -7.43 | -6.66 | -5.78 | -24.35 |
| Quality | ||||
| ROIC | -76.65% | -56.92% | -35.34% | -14.62% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.70 | 0.96 | 0.88 | 1.26 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 44.34% | -50.68% | -6.86% | -14.87% |
| Safety | ||||
| Net Debt / EBITDA | 0.47 | 0.32 | 2.70 | 6.55 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -485.43 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.04 | 0.07 |
| Cash Conversion Cycle | 0.00 | -2,589.24 | -63,528.59 | -8,156.50 |